BR112017004535A2 - esteroides neuroativos, composições e utilizações deste - Google Patents

esteroides neuroativos, composições e utilizações deste

Info

Publication number
BR112017004535A2
BR112017004535A2 BR112017004535-4A BR112017004535A BR112017004535A2 BR 112017004535 A2 BR112017004535 A2 BR 112017004535A2 BR 112017004535 A BR112017004535 A BR 112017004535A BR 112017004535 A2 BR112017004535 A2 BR 112017004535A2
Authority
BR
Brazil
Prior art keywords
compositions
neuroactive steroids
neuroactive
steroids
Prior art date
Application number
BR112017004535-4A
Other languages
English (en)
Inventor
Jay Kanes Stephen
Colquhoun Helen
Original Assignee
Sage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.
Publication of BR112017004535A2 publication Critical patent/BR112017004535A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017004535-4A 2014-09-08 2015-09-08 esteroides neuroativos, composições e utilizações deste BR112017004535A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462047599P 2014-09-08 2014-09-08
US62/047,599 2014-09-08
US201562170596P 2015-06-03 2015-06-03
US62/170,596 2015-06-03
US201562213015P 2015-09-01 2015-09-01
US62/213,015 2015-09-01
PCT/US2015/048937 WO2016040322A1 (en) 2014-09-08 2015-09-08 Neuroactive steroids, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
BR112017004535A2 true BR112017004535A2 (pt) 2018-07-03

Family

ID=55459478

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004535-4A BR112017004535A2 (pt) 2014-09-08 2015-09-08 esteroides neuroativos, composições e utilizações deste

Country Status (18)

Country Link
US (2) US20170348327A1 (pt)
EP (1) EP3191101A4 (pt)
JP (3) JP6837430B2 (pt)
KR (2) KR102491549B1 (pt)
CN (2) CN117679426A (pt)
AU (3) AU2015315333A1 (pt)
BR (1) BR112017004535A2 (pt)
CA (1) CA2960611A1 (pt)
CO (1) CO2017003396A2 (pt)
IL (2) IL285703B2 (pt)
JO (2) JOP20200195A1 (pt)
MX (2) MX2017003037A (pt)
PE (2) PE20221050A1 (pt)
PH (1) PH12017500427A1 (pt)
RU (2) RU2020127610A (pt)
SG (2) SG10202107866YA (pt)
TW (3) TWI688389B (pt)
WO (1) WO2016040322A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
EP3215965A1 (en) * 2014-11-06 2017-09-13 Ieso Digital Health Limited Computer-based system for providing psychological therapy
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
AU2016214996B2 (en) * 2015-02-06 2021-03-04 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
IL302480A (en) 2016-08-23 2023-06-01 Sage Therapeutics Inc 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018147791A1 (en) 2017-02-10 2018-08-16 Asarina Pharma Ab 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
MX2019008763A (es) * 2017-02-10 2019-10-21 Asarina Pharma Ab 3-beta-hidroxi-5-alfa-pregnan-20-ona para uso en tratamiento medico.
US20220062165A1 (en) * 2018-04-17 2022-03-03 M et P Pharma AG Compositions and methods for intranasal delivery of pregnenolone
CN117959309A (zh) * 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
JP2022511673A (ja) * 2018-11-05 2022-02-01 オービッド・セラピューティクス・インコーポレイテッド 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
CN111281877A (zh) * 2018-11-22 2020-06-16 南京诺瑞特医药科技有限公司 神经活性类固醇的新制剂
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
US20200188358A1 (en) * 2018-12-14 2020-06-18 Praxis Precision Medicines, Inc. Methods for the treatment of depression
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
JP2023503928A (ja) 2019-12-06 2023-02-01 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
US20230091716A1 (en) * 2020-02-12 2023-03-23 Glia, Llc Progesterone Combinations
CA3176854A1 (en) 2020-03-25 2021-09-30 Sage Therapeutics, Inc. Use of agents for treatment of respiratory conditions
US11337987B1 (en) 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US20240173335A1 (en) * 2022-08-29 2024-05-30 Lipocine Inc. Oral Allopregnanolone Compositions and Methods of Use
WO2024054875A2 (en) * 2022-09-07 2024-03-14 Oxeia Biopharmaceuticals, Inc. Treatment of mild traumatic brain injury

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CZ292881B6 (cs) * 1994-11-23 2003-12-17 Euro-Celtique S.A. Androstanová a pregnanová řada pro allosterickou modulaci GABA receptoru
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6316613B1 (en) 1997-07-25 2001-11-13 Beckman Coulter, Inc. Chiral separation of pharmaceutical compounds with charged cyclodextrins using capillary electrophoresis
EP1218003A4 (en) * 1999-09-13 2004-02-11 David M Swope COMPOSITION AND METHOD FOR REDUCING NEUROLOGICAL SYMPTOMATOLOGY
EP1216713A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
SE0104423D0 (sv) * 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
US7122593B2 (en) 2002-01-14 2006-10-17 Ansell Healthcare Products Llc Magnetically detectable latex articles
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1626980A4 (en) 2003-05-29 2007-07-04 Univ Washington NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
EP1591455A1 (en) * 2004-04-29 2005-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Essential tremor diagnostic and treatment
ITMI20041763A1 (it) 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
WO2006037016A2 (en) * 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
ES2589139T3 (es) 2007-06-15 2016-11-10 Research Triangle Institute Esteroides de androstano y pregnano con potentes propiedades de modulación alostérica del complejo receptor GABA/ionóforo cloruro
WO2010107922A1 (en) * 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
ES2738526T3 (es) 2011-10-14 2020-01-23 Sage Therapeutics Inc Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3957309A1 (en) * 2012-08-21 2022-02-23 Sage Therapeutics, Inc. Preparation of a composition comprising allopregnanolone and sulfobutylether-beta-cyclodextrin
JP2016501876A (ja) * 2012-11-30 2016-01-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ステロイドの抗痙攣活性
RU2663665C2 (ru) 2012-12-18 2018-08-08 Вашингтон Юниверсити Нейроактивные 19-алкокси-17-замещенные стероиды и способы лечения с их применением
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
SG11201508550XA (en) 2013-04-17 2015-11-27 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof
CA2909546C (en) 2013-04-17 2019-01-22 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SI3021852T1 (sl) 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporabe le-teh
EP3035940B1 (en) 2013-08-23 2018-10-17 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Also Published As

Publication number Publication date
MX2017003037A (es) 2017-06-14
US20170348327A1 (en) 2017-12-07
AU2015315333A1 (en) 2017-03-23
AU2021202433B2 (en) 2023-07-13
WO2016040322A1 (en) 2016-03-17
RU2017111816A (ru) 2018-10-10
PE20221050A1 (es) 2022-06-30
US20200253985A1 (en) 2020-08-13
KR20230015518A (ko) 2023-01-31
AU2021202433C1 (en) 2024-01-25
SG10202107866YA (en) 2021-08-30
JP2022113879A (ja) 2022-08-04
JOP20200195A1 (ar) 2017-06-16
EP3191101A4 (en) 2018-04-11
KR102491549B1 (ko) 2023-01-20
CA2960611A1 (en) 2016-03-17
IL285703A (en) 2021-09-30
TWI784261B (zh) 2022-11-21
TWI688389B (zh) 2020-03-21
TW202329978A (zh) 2023-08-01
JP2017526703A (ja) 2017-09-14
KR20170048567A (ko) 2017-05-08
CN117679426A (zh) 2024-03-12
JP6837430B2 (ja) 2021-03-03
AU2021202433A1 (en) 2021-05-13
TW201625266A (zh) 2016-07-16
RU2020127610A (ru) 2021-09-30
PE20170904A1 (es) 2017-07-12
JP2020059760A (ja) 2020-04-16
JO3667B1 (ar) 2020-08-27
AU2023248120A1 (en) 2023-11-02
IL285703B2 (en) 2024-03-01
SG11201701815SA (en) 2017-04-27
CO2017003396A2 (es) 2017-08-31
IL250942A0 (en) 2017-04-30
IL285703B1 (en) 2023-11-01
CN107106574A (zh) 2017-08-29
TW202106306A (zh) 2021-02-16
EP3191101A1 (en) 2017-07-19
PH12017500427A1 (en) 2017-07-31
IL250942B (en) 2021-09-30
RU2017111816A3 (pt) 2019-05-08
RU2731000C2 (ru) 2020-08-26
MX2020011537A (es) 2020-11-24

Similar Documents

Publication Publication Date Title
IL292461A (en) Neuroactive steroids, preparations and their uses
IL285703A (en) Neuroactive steroids, preparations and their uses
HK1258616A1 (zh) 神經活性類固醇、組合物、及其用途
DK3258939T3 (da) Neuroaktive steroider, sammensætninger og anvendelser heraf
DK3361870T3 (da) Fungicidsammensætninger
DK3021852T3 (da) Neuroaktive steroider, sammensætninger og anvendelser deraf
DK3488852T3 (da) Neuroaktive steroider, sammensætninger og anvendelser deraf
BR112017007053A2 (pt) compostos neuroativos e métodos de utilização deste composto.
DK3542812T3 (da) Glycopeptidsammensætninger
KR20180084891A (ko) 구조 조성물 및 방법
DK3040326T3 (da) Haloolefin-baseret sammensætning
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
CL2017000639A1 (es) Composición
DK3200827T3 (da) Sammensætninger
DK3337322T3 (da) Fungicidsammensætninger
CL2016002704A1 (es) Composiciones estables de péptidos neuroactivos.
DK3212800T3 (da) 21-hydroxylering af steroider
TH1601003983A (th) องค์ประกอบของแป้ง
TH1601000561A (th) สารกระจาย
LU92458B1 (fr) Composition amincissante

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023012741-2 PROTOCOLO 870230054435 EM 23/06/2023 16:50.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]